A61P 11/02
Nasal agents
Official title: Nasal agents, e.g. decongestants
A61P11/02 (Nasal agents) appears on 5,063 US grants and 7,780 published applications in this corpus.
Search patents in A61P- Granted patents
- 5,063
- Published applications
- 7,780
- Assignees
- 2,065
- Inventors
- 12,183
- Latest grant
- 18 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 2 | 0 |
| 1977 | 0 | 0 |
| 1978 | 0 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 2 | 0 |
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 2 | 0 |
| 1995 | 2 | 0 |
| 1996 | 7 | 0 |
| 1997 | 17 | 0 |
| 1998 | 23 | 0 |
| 1999 | 26 | 0 |
| 2000 | 35 | 0 |
| 2001 | 70 | 25 |
| 2002 | 99 | 119 |
| 2003 | 86 | 197 |
| 2004 | 87 | 385 |
| 2005 | 105 | 333 |
| 2006 | 124 | 363 |
| 2007 | 150 | 389 |
| 2008 | 160 | 416 |
| 2009 | 216 | 515 |
| 2010 | 276 | 647 |
| 2011 | 310 | 586 |
| 2012 | 405 | 601 |
| 2013 | 445 | 454 |
| 2014 | 458 | 470 |
| 2015 | 331 | 371 |
| 2016 | 297 | 370 |
| 2017 | 283 | 330 |
| 2018 | 250 | 267 |
| 2019 | 209 | 213 |
| 2020 | 177 | 200 |
| 2021 | 113 | 143 |
| 2022 | 90 | 110 |
| 2023 | 67 | 85 |
| 2024 | 62 | 87 |
| 2025 | 50 | 64 |
| 2026 | 26 | 40 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Methods for treating nasal polyposis by administering an IL-4R antagonist18 Aug 2026US 12,709,642 B2Regeneron Pharmaceuticals, Inc.
- Methods for treating chronic rhinosinusitis with nasal polyps by administering an antibody antagonist of IL-4R11 Aug 2026US 12,702,709 B2Regeneron Pharmaceuticals, Inc.
- N-acetylneuraminic acid compositions and methods of use21 Jul 2026US 12,685,741 B2LifeScience AS
- Compositions and use of varenicline for treating dry eye16 Jun 2026US 12,653,824 B2Oyster Point Pharma, Inc.
- Fused ring compound and pharmaceutical containing same16 Jun 2026US 12,655,147 B1Kaken Pharmaceutical Co., Ltd.
- Method for preparing aromatic essential oil for clearing nasal passages24 Sep 2026US 2026/0284135 A1Zhuhai Hengqin Gende Biotechnology Co., Ltd.
- Intranasal epinephrine formulations and methods of use10 Sep 2026US 2026/0263387 A1ARS Pharmaceuticals Operations, Inc.
- Fc region variant27 Aug 2026US 2026/0250360 A1Chugai Seiyaku Kabushiki Kaisha
- Methods for treating igg4-related diseases27 Aug 2026US 2026/0250393 A1Xencor, Inc.
- Nitrogen-containing spiro cyclic compounds and pharmaceutical use thereof20 Aug 2026US 2026/0242385 A1
Most cited
By later US patents
- Imidazonaphthyridines255US 6,194,425 B13M Innovative Properties Company · 2001
- Amide substituted imidazoquinolines237US 6,451,810 B13M Innovative Properties Company · 2002
- Identification and engineering of antibodies with variant Fc regions and methods of using same227US 7,355,008 B2MacroGenics, Inc. · 2008
- Albumin fusion proteins comprising GLP-1 polypeptides198US 7,141,547 B2Human Genome Sciences, Inc. · 2006
- Bi-aryl meta-pyrimidine inhibitors of kinases194US 7,528,143 B2TargeGen, Inc. · 2009